Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study.
The effect of Bellergal Retard (BR) on climacteric complaints was evaluated versus a placebo in an 8-wk double-blind study, followed by a 4-wk open study in which only BR was used as medication. There was a marked decrease in complaints in both the BR and the placebo groups. Statistically significant differences were observed between the groups after 2 and 4 wk of treatment, indicating superior results with BR. After 8 wk of study however, these differences were no longer apparent. It was concluded that studies on medication for climacteric complaints should not only be placebo-controlled, but also be of at least 8 to 12 wk duration for proper evaluation.
Bergmans
M G
MG
Department of Obstetrics and Gynaecology, Maria Ziekenhuis, Tilburg, The Netherlands.
Merkus
J M
JM
Corbey
R S
RS
Schellekens
L A
LA
Ubachs
J M
JM
D001533:Belladonna Alkaloids; D002979:Climacteric / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D004879:Ergotamines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008784:Methysergide / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010634:Phenobarbital / Q000009:adverse effects / Q000627:therapeutic use*; D013546:Sweating / Q000187:drug effects
D001533:Belladonna Alkaloids; D004338:Drug Combinations; D004879:Ergotamines; C044435:belladonna alkaloid, ergotamine, phenobarbital drug combination; D008784:Methysergide; D010634:Phenobarbital